CHICAGO (Reuters) - Drugmaker Eli Lilly and Co said on Thursday its late-stage lung cancer study failed to meet its primary goal of improved overall survival for patients with nonsquamous non-small cell lung cancer.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment